{"DataElement":{"publicId":"4648632","version":"1","preferredName":"Patient Protocol Agent Allergic Reaction Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a history of allergic reactions to the study agent or to compounds of similar chemical or biologic composition.","longName":"PXA_ALG_RX_PMH_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4647714","version":"1","preferredName":"Patient Protocol Agent Allergic Reaction Personal Medical History","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._A medical product, practice, or application that is tested in a clinical trial._An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures._A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures._A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","longName":"2177068v1.0:4647712v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4648631","version":"1","preferredName":"Protocol Agent Allergic Reaction Personal Medical History","preferredDefinition":"A medical product, practice, or application that is tested in a clinical trial.:An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.:A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","longName":"C41161:C114476:C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Agent","conceptCode":"C41161","definition":"A medical product, practice, or application that is tested in a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Allergic Reaction","conceptCode":"C114476","definition":"An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FD70-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"ONEDATA","dateModified":"2015-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B756BB6-D9C5-6F29-E050-BB89AD437002","latestVersionIndicator":"Yes","beginDate":"2014-12-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9466_Theradex_12.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Does patient have a history o","type":"Preferred Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient have a known hypersensitivity to olaparib or any of the excipients of the product?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab and/or ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have known sensitivity to the active or inactive excipients of AZD6094?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have known sensitivity to the active or inactive excipients of AZD6090?","url":null,"context":"Theradex"},{"name":"NRG CRF TEXT 1","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide?","url":null,"context":"NRG"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, nivolumab, and ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent(s) (e.g., benzodiazepines for GSK525762C)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Radium-223 dichloride or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620, avelumab, gemcitabine, carboplatin, or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have a history of any clinically significant drug allergy or hypersensitivity to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, nivolumab, and ipilimumab (such as anaphylaxis or hepatotoxicity)?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR or Capecitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 (peposertib) or Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or CPX-351 or their excipients?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient have a history of allergic reaction or hypersensitivity attributed to compounds of similar chemical or biologic composition to abemaciclib, olaparib or any of the excipients of these products?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or lomustine?","url":null,"context":"NRG"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to erdafitinib and enfortumab vedotin?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax, ASTX727, or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions or sensitivities attributed to compounds of similar chemical or biologic composition to SGI-110 (guadecitabine), its active metabolite decitabine, or ASTX727 or belinostat?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab, cobimetinib, or CDX-1127 (varlilumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or other agents used in study?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or Gleostine?","url":null,"context":"NRG"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical composition to study drugs?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient have an allergy to fish, shellfish, or omega-3 unsaturated fatty acid?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab or selinexor?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to erdafitinib or atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CA-4948 or other agents in study?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727 or venetoclax?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) and M1774?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727, pembrolizumab (MK-3475), and/or paclitaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to TAK-243?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to APG-1252 or cobimetinib?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CBX-12 (e.g., other topoisomerase I inhibitors) or the inactive ingredients in the drug product?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, or ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to erdafitinib?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to mosunetuzumab or rituximab?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to SNDX-5613, daunorubicin or cytarabine?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, gemcitabine, cisplatin, or other platinum-containing compounds?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Selinexor (KPT-330) or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or other agents used in study?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FD85-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeDescription":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}